Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Johnson and Johnson
Merck
Mallinckrodt
Baxter

Last Updated: June 29, 2022

Patent: 8,889,661


✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,889,661
Title:Treatment of lupus nephritis using laquinimod
Abstract: This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis.
Inventor(s): Haviv; Asi (Kvutsat Shiller, IL), Tarcic; Nora (Modiin, IL)
Assignee: Teva Pharmaceutical Industries, Ltd. (Petach-Tikva, IL)
Application Number:13/039,178
Patent Claims:see list of patent claims

Details for Patent 8,889,661

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 See Plans and Pricing 2030-03-03
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 See Plans and Pricing 2030-03-03
Bristol-myers Squibb Company ORENCIA abatacept For Injection 125118 12/23/2005 See Plans and Pricing 2030-03-03
Bristol-myers Squibb Company ORENCIA abatacept Injection 125118 07/29/2011 See Plans and Pricing 2030-03-03
Bristol-myers Squibb Company ORENCIA abatacept Injection 125118 06/07/2016 See Plans and Pricing 2030-03-03
Bristol-myers Squibb Company ORENCIA abatacept Injection 125118 03/30/2017 See Plans and Pricing 2030-03-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Baxter
Boehringer Ingelheim
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.